{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-272891","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.798443+00:00","generated_at":"2026-05-29T05:45:57.649524+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vor Bio announces positive clinical data for trem-cel + Mylotarg in AML; FDA agrees on registrational trial design","bullets":["Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.","Engraftment achieved in 100% of patients: neutrophil engraftment median 9.5 days, platelet recovery median 16 days.","CD33 editing efficiency median 90% (range 71-94%); doses up to 2 mg/m2 without significant toxicity.","FDA agreed on registrational trial design for trem-cel + Mylotarg, including study population, control arm, primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-272891","json":"https://secwatch.observer/filing/0001193125-24-272891.json","markdown":"https://secwatch.observer/filing/0001193125-24-272891.md","text":"https://secwatch.observer/filing/0001193125-24-272891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/0001193125-24-272891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/d818014d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:45:57.649524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}